Education
About Us
Working with TipRanks
Follow Us
Arcturus Therapeutics (ARCT)
NASDAQ:ARCT
ARCT Analyst Ratings
Strong Buy
11 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
ARCT Stock 12 Month Forecast
Average Price Target
$61.44
▲(401.14%Upside)
| Highest Price Target$140.00 | Average Price Target$61.44 | Lowest Price Target$32.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
TipRanks
$12.5
Hold
1.96%
Upside
Reiterated
06/05/25
Arcturus Therapeutics' overall score reflects a blend of financial challenges and technical resilience. Financial performance is constrained by consistent losses and declining revenue, but technical indicators show short-term bullish trends. The company's strategic focus on mRNA therapeutics and extended cash runway are positive, though valuation remains weak due to a negative P/E ratio.
Scotiabank
$32
Buy
161.01%
Upside
Initiated
05/28/25
William Blair
―
Buy
―
Reiterated
05/21/25
Wells Fargo
$50→$45
Buy
267.05%
Upside
Reiterated
05/14/25
Canaccord Genuity
$68→$66
Buy
438.34%
Upside
Reiterated
05/13/25
Cantor Fitzgerald
―
Buy
―
Reiterated
05/13/25
Citi
$44
Buy
258.89%
Upside
Reiterated
05/12/25
Leerink Partners
$63
Buy
413.87%
Upside
Reiterated
05/12/25
H.C. Wainwright
$60
Buy
389.40%
Upside
Reiterated
04/11/25
Guggenheim
$71→$45
Buy
267.05%
Upside
Reiterated
04/10/25
BTIG
$57→$58
Buy
373.08%
Upside
Reiterated
03/27/25
Piper Sandler
$140
Buy
1041.92%
Upside
Reiterated
03/07/25
Laidlaw
$79
Buy
544.37%
Upside
Reiterated
07/02/24
WBB Securities
$25
Buy
103.92%
Upside
Upgraded
06/30/24
We arrive at our valuation using a sum-of-the-parts model: We assign a per-share value of $10.00 to the Lunar-OTC program and $9.00 to the LUNAR-CF program. And the balance of $6.00 to the different vaccine programs. Thus, we arrive at a 12- month per share price target of $25.00.
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
TipRanks
$12.5
Hold
1.96%
Upside
Reiterated
06/05/25
Arcturus Therapeutics' overall score reflects a blend of financial challenges and technical resilience. Financial performance is constrained by consistent losses and declining revenue, but technical indicators show short-term bullish trends. The company's strategic focus on mRNA therapeutics and extended cash runway are positive, though valuation remains weak due to a negative P/E ratio.
Scotiabank
$32
Buy
161.01%
Upside
Initiated
05/28/25
William Blair
―
Buy
―
Reiterated
05/21/25
Wells Fargo
$50→$45
Buy
267.05%
Upside
Reiterated
05/14/25
Canaccord Genuity
$68→$66
Buy
438.34%
Upside
Reiterated
05/13/25
Cantor Fitzgerald
―
Buy
―
Reiterated
05/13/25
Citi
$44
Buy
258.89%
Upside
Reiterated
05/12/25
Leerink Partners
$63
Buy
413.87%
Upside
Reiterated
05/12/25
H.C. Wainwright
$60
Buy
389.40%
Upside
Reiterated
04/11/25
Guggenheim
$71→$45
Buy
267.05%
Upside
Reiterated
04/10/25
BTIG
$57→$58
Buy
373.08%
Upside
Reiterated
03/27/25
Piper Sandler
$140
Buy
1041.92%
Upside
Reiterated
03/07/25
Laidlaw
$79
Buy
544.37%
Upside
Reiterated
07/02/24
WBB Securities
$25
Buy
103.92%
Upside
Upgraded
06/30/24
We arrive at our valuation using a sum-of-the-parts model: We assign a per-share value of $10.00 to the Lunar-OTC program and $9.00 to the LUNAR-CF program. And the balance of $6.00 to the different vaccine programs. Thus, we arrive at a 12- month per share price target of $25.00.
Best Analysts Covering Arcturus Therapeutics
1 Month
xxx
Success Rate
7/10 ratings generated profit
Average Return
-4.03%
reiterated a xxx
rating 25 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 70.00% of your transactions generating a profit, with an average return of -4.03% per trade.
3 Months
xxx
Success Rate
4/9 ratings generated profit
Average Return
-5.28%
reiterated a xxx
rating 25 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 44.44% of your transactions generating a profit, with an average return of -5.28% per trade.
1 Year
Success Rate
2/9 ratings generated profit
Average Return
-29.24%
reiterated a buy rating 25 days ago
Copying Yigal Nochomovitz's trades and holding each position for 1 Year would result in 22.22% of your transactions generating a profit, with an average return of -29.24% per trade.
2 Years
xxx
Success Rate
4/18 ratings generated profit
Average Return
-27.07%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 22.22% of your transactions generating a profit, with an average return of -27.07% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
ARCT Analyst Recommendation Trends
Rating
Jan 25
Feb 25
Mar 25
Apr 25
May 25
Strong Buy
12
14
19
15
16
Buy
4
3
4
5
7
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
16
17
23
20
23
Each month's total comprises the sum of three months' worth of ratings.
ARCT Financial Forecast
ARCT Stock Forecast FAQ
What is ARCT’s average 12-month price target, according to analysts?
Based on analyst ratings, Arcturus Therapeutics’s 12-month average price target is 61.44.
What is ARCT’s upside potential, based on the analysts’ average price target?
Arcturus Therapeutics has 401.14% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is ARCT a Buy, Sell or Hold?
Arcturus Therapeutics has a consensus rating of Strong Buy which is based on 11 buy ratings, 0 hold ratings and 0 sell ratings.
What is Arcturus Therapeutics’s price target?
The average price target for Arcturus Therapeutics is 61.44. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $140.00 ,the lowest forecast is $32.00. The average price target represents 401.14% Increase from the current price of $12.26.
The highest analyst price target is $140.00 ,the lowest forecast is $32.00. The average price target represents 401.14% Increase from the current price of $12.26.
What do analysts say about Arcturus Therapeutics?
Arcturus Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 11 Wall Streets Analysts.
How can I buy shares of ARCT?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.